Lipanthyl NT, containing the active ingredient fenofibrate, is used to provide supportive therapeutic benefit by helping to manage elevated levels of cholesterol and triglycerides in the blood. This management is an essential part of addressing symptoms related to systemic imbalance caused by dyslipidemia.

---

Supportive Management of Dyslipidemia Manifestations

Fenofibrate is commonly used to help manage elevated blood fat levels in conditions such as primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia. The medication is generally relevant in clinical settings where long-term management of these factors is appropriate, thus contributing to easing the overall symptom burden over time. Fenofibrate is indicated as an adjunct to diet.

---

Addressing High-Risk Symptom Groups

This approach is applied across domains where additional symptomatic support is needed, particularly when groups of symptoms create noticeable physiological strain or may become intense. By providing supportive relief, the treatment assists with maintaining functional stability and helps patients cope more steadily with the underlying metabolic condition.

---

Quick Fact: Relief for Systemic Imbalance

Lipanthyl NT supports patients during episodes of heightened discomfort by addressing symptoms related to systemic imbalance caused by high blood fat levels.

Regulatory References

1. NIH DailyMed Label for Fenofibrate

Who can and cannot use Lipanthyl NT?

This section details the population eligibility and restrictions for Lipanthyl NT (Fenofibrate), based solely on official regulatory documents.

---

Eligibility Scope

Category	Official Regulatory Status
Populations for whom use is allowed	Adult Patients (Standard labeled use); Older Adults (Permitted, with dose selection based on renal function).
Populations for whom use is not recommended	Pediatric Population (Safety and efficacy not established); Hepatic Impairment (Not recommended due to lack of adequate data).
Populations for whom use is contraindicated	Severe Renal Dysfunction (including dialysis patients); Active Liver Disease; Pre-existing Gallbladder Disease; Nursing Mothers; Known Hypersensitivity to fenofibrate or related substances.

---

Condition-Specific and Age-Related Rules

Eligibility is conditional for mild to moderate renal impairment, requiring careful initiation and monitoring. Pregnancy status is conditional, where use is permitted only after a thorough benefit-risk assessment. Use is also contraindicated with a history of photoallergy or phototoxicity related to fibrates.

Connection to the overall eligibility profile: Regulatory documents define use by imposing absolute exclusions based on severe end-organ impairment, reproductive status, and hypersensitivity. The adult population is the primary allowed group, with strict conditional restrictions placed on pediatric use and less severe renal impairment.

Lipanthyl NT (fenofibrate) has officially documented interactions across metabolic, pharmacodynamic, and physical absorption domains that necessitate specific constraints on co-administration.

The co-administration with HMG-CoA Reductase Inhibitors (statins) or colchicine results in a recognized pharmacodynamic risk of serious muscle toxicity (myopathy and rhabdomyolysis). This interaction risk is formally noted as being higher in populations with renal impairment, diabetes, or those who are elderly. Furthermore, interaction with immunosuppressants such as cyclosporine officially carries a risk of renal function deterioration.

Fenofibrate exhibits pharmacokinetic interactions as a mild-to-moderate inhibitor of CYP2C9 and a weak inhibitor of CYP2C19. This metabolic action may increase the exposure of co-administered CYP2C9 substrates, such as certain narrow therapeutic index drugs. For coumarin anticoagulants (like Warfarin), fenofibrate potentiates their effect, leading to a prolonged clotting time and requiring a mandatory dosage reduction of the anticoagulant at the start of therapy.

A mandatory timing rule exists for substances that bind in the gut: Fenofibrate must be administered at least one hour before or four to six hours after bile-acid binding resins to prevent interference with absorption. Additionally, the label notes that a high-fat meal increases fenofibrate absorption.

How Lipanthyl NT Works

Fenofibrate’s mechanism is initiated by its active metabolite, fenofibric acid, which functions as an agonist for the Peroxisome Proliferator-Activated Receptor alpha ( PPARalpha) nuclear receptor. This interaction fundamentally alters the liver’s gene transcription profile regarding fat metabolism.

Activation of PPARalpha triggers a dual cascade: it causes the upregulation of Lipoprotein Lipase ( LPL), the enzyme responsible for breaking down circulating fats, and simultaneously drives the downregulation of Apolipoprotein C-III ( ApoC-III), which is a key inhibitor of LPL. This shift increases the system's enzymatic capacity to accelerate the clearance of triglyceride-rich particles like Very Low-Density Lipoprotein ( VLDL) from the plasma.

Furthermore, the transcriptional modulation targets the synthesis of key apoproteins, causing an increase in Apolipoprotein A-I and A-II production. These proteins are structural components of High-Density Lipoprotein ( HDL). This gene-mediated alteration in synthesis supports the formation and maintenance of higher levels of HDL, contributing to a significant alteration of the circulating lipoprotein profile.

How Lipanthyl NT is Used in Practice

Fenofibrate, the active component of Lipanthyl NT, is administered through the oral route as a whole film-coated tablet. The standardized schedule for all approved adult indications is a once-daily intake, establishing the consistent pattern necessary for long-term therapeutic use. For patients with primary hypercholesterolemia or mixed dyslipidemia, the usual starting and maintenance dose is 145 mg once per day.

Administration is flexible concerning meal timing: this specific 145 mg formulation can be taken with or without food. Crucially, the tablet must always be swallowed whole and must not be crushed, dissolved, or chewed, as altering the dosage form is counter to the documented instruction for use.

A key procedural rule exists when co-administering with other lipid-modifying agents such as bile acid resins; fenofibrate must be taken at least one hour before or four to six hours after the resin to prevent impaired absorption. Dosage adjustment, if required, is a structured process that should only occur after four to eight weeks following repeat lipid evaluations at the maximum dose. The use of fenofibrate is officially not recommended for the pediatric population, and a reduced daily dose is mandated for patients with mild-to-moderate renal impairment to prevent drug accumulation.

Research evidence / Overview of studies for Lipanthyl NT

---

Evidence for use in Managing High Cholesterol and Triglycerides

The research foundation for Lipanthyl NT includes large Randomized Controlled Trials (RCTs) and meta-analyses, which was studied for use as an adjunct to diet in adults with primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia. Studies primarily monitored changes in key lipid biomarkers, such as Triglycerides (TG) and HDL-C (often called 'good' cholesterol).

Research highlights changes measured during the study period, including measurements of lower measured TG levels and higher measured HDL-C levels. However, long-term trials monitoring composite cardiovascular events in the overall study population did not reach a predefined threshold for the main research goal. Findings related to cardiovascular endpoints were mixed and often limited to pre-specified, high-risk patient subgroups. The research provides limited insight into consistent, overall patterns for cardiovascular protection across the total dyslipidemia population.

---

Evidence from Studies in Type 2 Diabetes Mellitus

Dedicated research, including large-scale RCTs, has explored the use of Lipanthyl NT in adults with Type 2 Diabetes and high blood fat levels. These studies examined specific microvascular outcomes related to diabetes complications, such as the progression of albuminuria (a kidney function marker) and the development of retinopathy (eye disease).

Studies reported patterns of measurement regarding the progression of diabetic eye disease and albuminuria progression. However, similar to other major trials, long-term T2DM studies monitoring major composite cardiovascular outcomes did not meet the main endpoint. Research is still clarifying the interpretation and clinical significance of these findings.

---

Long-Term Studies and What is Still Uncertain

The research base includes trials designed with long-term follow-up periods, some lasting up to five years, which were conducted to measure the incidence of chronic events. This research provides context regarding the duration of the changes measured in blood fat levels during the defined study intervals, but research does not determine whether an individual will respond similarly beyond the study duration.

Data for certain groups, such as pediatric populations, data for certain groups remain insufficient for long-term outcomes. The main research limitation is that the long-term effects are not fully established for the overall reduction of major cardiovascular events.

Key Studies & References

1. Action to Control Cardiovascular Risk in Diabetes Lipid Trial (ACCORD Lipid) Summary
2. Australian TGA Public Summary (AusPAR) for Fenofibrate - Diabetic Retinopathy Indication Review

Common questions about Lipanthyl NT (FAQ)

---

Q: Will I feel any different when I start taking Lipanthyl NT?

It is possible to experience certain changes after starting the medicine. Official product information reports that side effects like headache, general stomach pain, or nausea and vomiting are among the common or uncommon reactions people may experience when taking the medicine.

---

Q: Can people with diabetes safely take Lipanthyl NT?

Regulatory documents note that fenofibrate has been studied in patients with Type 2 Diabetes Mellitus to help manage their lipid levels. However, official warnings note that patients with diabetes who take fenofibrate in combination with a statin is associated with an increased risk of serious muscle toxicity.

---

Q: Is Lipanthyl NT used as a long-term treatment or is it usually temporary?

Lipanthyl NT is generally intended for long-term use as a supportive therapy alongside a healthy diet. However, if the blood fat levels do not respond adequately after a period of time, such as two months at the maximum dose, therapy may be withdrawn by a healthcare provider.

---

Q: What should I do if I experience an unusual skin rash after starting Lipanthyl NT?

Regulatory labels state that skin reactions, including rash, itching, and hives (urticaria), have been reported. The drug has also been linked to photosensitivity (increased sun sensitivity). Experiencing these or any allergic symptoms should prompt contact with a healthcare professional.

---

Q: Does Lipanthyl NT have known interactions with common blood pressure medications?

Regulatory documents indicate that fenofibrate may interact with some blood pressure medications. Specifically, it has the potential to affect the effectiveness or increase the exposure of certain medicines, such as Angiotensin II Receptor Antagonists (a class of blood pressure drugs).

---

Q: Is there a generic version of Lipanthyl NT available?

Yes, the active ingredient in Lipanthyl NT is fenofibrate. Official product information confirms that fenofibrate is currently available in multiple generic formulations and various dosage strengths.

---

Q: Can Lipanthyl NT affect sleep patterns?

Official reports on side effects include insomnia (difficulty sleeping) as an adverse reaction seen in some clinical trials. If changes in sleep patterns are noticed, consultation with a healthcare provider is appropriate.

---

Q: Is it normal to be a little tired when taking Lipanthyl NT?

While not listed as a 'common' side effect, the regulatory label notes reports of asthenia, which is defined as unusual physical weakness or lack of energy. It is appropriate to discuss this with your healthcare provider if it becomes bothersome.

---

Q: What specific type of fat does Lipanthyl NT target most effectively?

Fenofibrate is designed to address a poor balance of fats in the blood. Official clinical information states that it is indicated to help lower elevated levels of triglycerides (TG) and clearing Very Low-Density Lipoprotein (VLDL) particles from the bloodstream.

---

Q: Are there any known effects of Lipanthyl NT on mood or mental clarity?

Regulatory and post-marketing data have included reports of effects on mood and mental state. These reports have included anxiety, nervousness, and depression.

---

Q: What are the specific components of the 'Interactions with other medicines' section for Lipanthyl NT?

Official drug labels highlight the potential for interactions with several types of medicines. These include statins, coumarin anticoagulants, certain immunosuppressants (like Cyclosporine), and bile-acid binding resins.

---

Q: Is Lipanthyl NT known to cause any hair loss?

Regulatory documents list alopecia (hair loss) as an adverse reaction that has been reported, though it is considered a rare event from post-marketing surveillance. If this side effect persists or is severe, it should be brought to the attention of a healthcare provider.

---

Q: Do you have to stop taking Lipanthyl NT before a surgery?

The decision regarding pre-operative use is made by the prescribing physician. Because the drug may potentiate the effects of coumarin anticoagulants (blood thinners), temporary interruption may be necessary before high-bleeding-risk procedures.

---

Q: Are there different forms of Lipanthyl besides the NT version?

Yes, the active ingredient, fenofibrate, is available in multiple tablet and capsule formulations and under various other brand names besides Lipanthyl NT.

---

Q: What is the typical dosage strength of Lipanthyl NT?

Lipanthyl NT is commonly provided as the 145 mg tablet. Fenofibrate is available in a range of strengths (e.g., 40 mg to 160 mg) depending on the specific product and formulation.

---

Q: What are the main benefits of Lipanthyl NT compared to not taking any medication for high lipids?

The regulatory indication is for use as an adjunct to diet to help correct dyslipidemia. Its purpose is to help lower elevated fats in the blood, including triglycerides and 'bad cholesterol' components, while also helping to increase HDL-C ('good cholesterol').

---

Q: How often do people usually need blood tests when they are on Lipanthyl NT?

Liver function and kidney function (renal function) monitoring is required periodically, particularly during the initial months of treatment. The exact schedule is set by your healthcare provider.

---

Q: Why is my doctor prescribing Lipanthyl NT instead of just a statin?

Fenofibrate belongs to the fibrate class, which is different from statins. It is often prescribed for patients with mixed dyslipidemia (high cholesterol and high triglycerides) or for severe hypertriglyceridemia, where the primary problem is very high triglycerides.

---

Q: Can Lipanthyl NT be taken by people who have had a history of stroke or heart attack?

Major clinical trials for fenofibrate included some patients with a history of cardiovascular events. However, official regulatory information notes that the overall research does not provide a definitive conclusion regarding the reduction of major cardiovascular events for all patient groups.

---

Q: What are the most common side effects people report when taking Lipanthyl NT?

Based on clinical trial data, the most common reported side effects (affecting between 1 in 10 and 1 in 100 people) are typically gastrointestinal symptoms (like nausea and stomach upset) and abnormal liver function tests, which your doctor monitors.

---

Q: Can Lipanthyl NT cause muscle aches, and is that normal?

Muscle-related issues like muscle aches (myalgia) and muscle cramps are known side effects, listed as uncommon (affecting 1 in 100 to 1 in 1,000 people). While serious muscle damage is rare, any persistent or unusual muscle pain should be reported to a healthcare provider.

---

Q: What are the signs of a serious, but rare, side effect from Lipanthyl NT?

Serious, though rare, side effects include severe muscle breakdown (rhabdomyolysis) and thromboembolic events (blood clots). Experiencing severe muscle pain, unexplained fever, or signs like pain/swelling in the legs or sudden shortness of breath are reasons to seek immediate medical attention.

---

Q: Why do some people take Lipanthyl NT in combination with a statin?

Lipanthyl NT is sometimes combined with a statin to treat mixed dyslipidemia (an imbalance involving both high triglycerides and high cholesterol). The combination approach is used to address the different lipid components simultaneously. Regulatory labels note that this combination is associated with an increased risk of muscle side effects.

---

Q: Is it normal to feel slightly nauseous when first starting Lipanthyl NT?

Gastrointestinal symptoms are listed as common side effects of fenofibrate. This includes feeling slightly nauseous or having stomach upset. If this side effect persists or is severe, it should be brought to the attention of a healthcare provider.

How to Store and Dispose of Lipanthyl NT?

The storage and disposal of Lipanthyl NT (fenofibrate) tablets must strictly follow official regulatory guidelines to maintain product quality and safety.

Storage Conditions

• Temperature: Store at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Do not allow the medication to freeze or be exposed to excessive heat.
• Protection: The tablets must be protected from moisture and humidity. Keep the product in its original, closed container to preserve stability.
• Child Safety: All medication must be stored out of the sight and reach of children.

Disposal Instructions

• Unused Medicine: Dispose of unused or expired Lipanthyl NT according to local pharmaceutical waste regulations.
• Environmental Rule: Do not dispose of the tablets by flushing them down a toilet or pouring them down a drain, unless specifically advised by a local take-back program.